IRIS
GIACOMELLI, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.531
EU - Europa 7.789
AS - Asia 3.805
Continente sconosciuto - Info sul continente non disponibili 37
OC - Oceania 27
SA - Sud America 18
AF - Africa 14
Totale 24.221
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.498
IE - Irlanda 2.531
CN - Cina 2.003
TR - Turchia 1.476
SE - Svezia 1.127
IT - Italia 935
DE - Germania 875
UA - Ucraina 818
GB - Regno Unito 620
FI - Finlandia 337
FR - Francia 300
IN - India 125
SG - Singapore 72
VN - Vietnam 63
BE - Belgio 55
RU - Federazione Russa 37
EU - Europa 34
CA - Canada 27
RO - Romania 26
CZ - Repubblica Ceca 22
AU - Australia 19
GR - Grecia 17
NL - Olanda 16
BR - Brasile 12
CH - Svizzera 12
BG - Bulgaria 10
ES - Italia 10
NZ - Nuova Zelanda 8
PT - Portogallo 8
QA - Qatar 8
KR - Corea 7
MY - Malesia 7
JP - Giappone 6
DK - Danimarca 5
EG - Egitto 5
HK - Hong Kong 5
IL - Israele 5
MK - Macedonia 4
PH - Filippine 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 3
AL - Albania 3
BD - Bangladesh 3
ET - Etiopia 3
HR - Croazia 3
IR - Iran 3
KE - Kenya 3
LT - Lituania 3
MX - Messico 3
PL - Polonia 3
AT - Austria 2
CO - Colombia 2
HU - Ungheria 2
ID - Indonesia 2
KW - Kuwait 2
LU - Lussemburgo 2
LV - Lettonia 2
PE - Perù 2
PK - Pakistan 2
RS - Serbia 2
AM - Armenia 1
AR - Argentina 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
EC - Ecuador 1
GE - Georgia 1
HN - Honduras 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
NG - Nigeria 1
NO - Norvegia 1
OM - Oman 1
PR - Porto Rico 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 24.221
Salva come PNG Salva come JPEG
Città #
Jacksonville 3.346
Chandler 2.675
Dublin 2.524
Izmir 830
Nanjing 554
Boardman 528
San Mateo 512
Wilmington 495
Lawrence 444
Princeton 444
New York 321
Ann Arbor 291
Beijing 258
Nanchang 221
Ashburn 216
L'aquila 164
Milan 161
L’Aquila 150
Dearborn 142
Woodbridge 135
Seattle 125
Verona 119
Shenyang 118
Des Moines 110
Hebei 103
Kunming 89
Tianjin 87
Jiaxing 82
Los Angeles 72
Mountain View 65
Dong Ket 60
Changsha 57
Jinan 57
Zhengzhou 56
Norwalk 55
Shanghai 54
Brussels 49
Singapore 43
Hangzhou 41
Ningbo 34
Philadelphia 33
Pune 33
Rome 33
Hefei 28
Guangzhou 26
Helsinki 26
Kitzingen 21
Lanzhou 21
Brno 19
Houston 18
Bremen 17
Taizhou 17
Redwood City 16
Bucharest 15
Changchun 14
Frankfurt am Main 14
Fremont 13
Fuzhou 12
Washington 12
Phoenix 11
Chengdu 10
Edinburgh 10
Falls Church 9
Grafing 9
Munich 9
Doha 8
Jinhua 8
Auburn Hills 7
Salerno 7
Cedar Knolls 6
Düsseldorf 6
Forest City 6
La Spezia 6
Moscow 6
Orange 6
Padova 6
Reggio Nell'emilia 6
Tappahannock 6
Athens 5
Brisbane 5
London 5
Naples 5
Raritan 5
Redmond 5
St Petersburg 5
Tokyo 5
West Jordan 5
Auckland 4
Chicago 4
Columbus 4
Leuven 4
Lisbon 4
Montreal 4
Mumbai 4
Ottawa 4
Plovdiv 4
Ponte A Égola 4
Shaoxing 4
Sofia 4
Sorrento 4
Totale 16.514
Salva come PNG Salva come JPEG
Nome #
------- 298
EULAR Textbook on Rheumatic Diseases – Third Edition (2018) 246
Aumento dei linfociti circolanti gamma-delta Vdelta1+ in corso di malattie infiammatorie intestinali 127
Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis 109
Factors influencing the patient evaluation of injection experience with the SmartJect autoinjector in rheumatoid arthritis. 101
FRI0613 H-ferritin and pro-inflammatory cytokines are increased in the bone marrow of adult patients affected by macrophage activation syndrome 99
Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients 97
Studio dell’espressione della chemochina SDF-1 e del suo recettore CXCR4 nella cute e nelle cellule endoteliali microvascolari di pazienti affetti da sclerosi sistemica (SSc). 94
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 93
The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: Correlation with disease severity and implication for pathogenesis 92
Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? 90
The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes 88
The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. 88
H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease 88
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 87
Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers 85
association of pathogenic and regulatory B-cell subsets with clinical and histological features in primary Sjogren's syndrome. 85
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts 84
Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: Results of a large multicentre study 83
Linfociti T Gamma-Delta (G/D) in pazienti con malattie infiammatorie intestinali (IBD) 83
Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis 83
Cytokine production in patients with monoclonal gammapathies. 81
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 80
PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis 80
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 79
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome 79
Stromal Cell-derived Factor 1 in Cardiac and Autoimmune Disease 78
Stem cell therapies for systemic sclerosis 77
A comprehensive review on adult onset Still's disease 77
Natural killer activity and antibody-dependent cellular cytotoxicity in progressive systemic sclerosis 77
Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population. 77
EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells 76
Comment on 'Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?' 76
GM-CSF and pregnancy: evidence of significantly reduced blood concentrations in unexplained recurrent abortion efficiently reverted by intravenous immunoglobulin treatment. 76
Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. 76
Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis 75
Familial autoimmunity as a risk factor for systemic lupus erythematosus and vice versa: a case-control study 75
Inosine pranobex in the combination therapy of HIV infection. 74
Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18. 74
IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? 74
Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. 74
GAMMA/DELTA T CELL APOPTOSIS IN SYSTEMIC SCLEROSIS PATIENTS 74
Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms 72
CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment. 72
Natural killer cell frequency and function in patients with monoclonal gammopathies. 72
The role of cytokines in the patogenesis of monoclonal gammapathies. 72
l'immunoterapia dei tumori 72
Malattie dell'apparato cardiovascolare 72
EFFICACY AND SAFETY OF RITUXIMAB TREATMENT IN EARLY PRIMARY SJOGREN'S SYNDROME: A CLINICAL, HISTOLOGICAL AND MOLECULAR STUDY 72
Cardiovascular disease in primary sjögren’s syndrome 72
The role of cytokines in the pathogenesis of PSS: an overview 72
Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population-based multicentre cohort study. 72
Combined approach to the initial stage raynaud’s phenomenon diagnosis by means of dynamic digital telehermograpy, capillaroscopy and pletismography. Preliminary findings. 71
Neoplasie e sistema immune 71
SENESCENT BONE MARROW DERIVED MESENCHYMAL STEM CELLS (MSC) ARE PRONE TO RECOVER DURING SSC 71
Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study 71
ALTERAZIONI DELLE SOTTOPOLAZIONI LINFOCITARIE IN CORSO DI SCLERODERMIA 71
Unmasking the pathogenic role of il-17 axis in primary sj¨ogren’s syndrome: A new era for therapeutic targeting? 71
T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives. 71
The expansion of NK CD56+ cells with reduced cytotoxicity in a female patient with systemic sclerosis 70
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. 70
Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. 69
Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization 69
Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers.. Epub 2002 Aug 30 69
Cyclosporin (CyA) and H2 antagonists 69
Immunosuppressive therapy of vasculitis: current aspects and perspectives 69
Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients 69
SAT0489 Biologic Therapies and Infections in The Daily Practice: A Study on Historical Cohort from 3 Italian Rheumatologic Units 69
Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. 69
Combined approach to the initial stage raynaud's phenomenon diagnosis by means of dynamic digital telethermography, capillaroscopy and pletismography preliminary findings. 68
Advances in treatment of rheumatoid arthritis 68
DUO Registry Group. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry. 68
Immuopathological demonstration of immune reagents in the kidneys of patient with nephrolithiasis 68
Biotech on the Rise: The Treatment of Psoriasis with Biological Drugs 68
Interleukin-9 Overexpression and Th9 Polarization Characterize the Inflamed Gut, the Synovial Tissue, and the Peripheral Blood of Patients With Psoriatic Arthritis 68
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. 68
Evidence of drug interaction between cyclosporin A and H2-receptor antagonists (cimetidine, ranitidine and famotidine) in Sprague-Dawley rats. 68
Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. 67
Decreased Expression of Angiopoetin 1 on Perivascular Mesenchymal Stem Cells from Ssc Patients Induces an Anti Angiogenetic Effect, when Co-cultured with Endothelial Cells 67
The Role of IL-1β in the Bone Loss during Rheumatic Diseases 67
NK activity and antibody-dependent cellular citotoxicity (ADCC) in inflammatory bowel disease(IBD) 67
Pollinosi in Abruzzo. Aspetti aerobiologici e clinici, triennio 1988-1990 67
Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. 67
Searching for a good model for systemic sclerosis: The molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis 67
Alterations in lymphocyte subpopulations in bronchiolitis 66
Antimyocardial autoimmunity in ischemic coronary disease 66
AIDS e neoplasie 66
Interstitial lung disease in systemic sclerosis: current and future treatment. 66
Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. 65
Differential expression of tissue kallikrein in the skin of systemic sclerosis 65
FAS -670 gene promoter polymorphism confers susceptibility to systemic sclerosis 65
CLINICAL PREDICTION OF 5-YEAR SURVIVAL IN EARLY SCLERODERMA: VALIDATION OF A SIMPLE PROGNOSTIC MODEL IN A MULTI-CENTRE STUDY 65
La eritematoviscerite maligna 65
The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. 65
Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications 64
Pupillocynetic activity of substance P in systemic sclerosis 64
BODY WEIGHT AND RESPONSE TO BIOLOGICS IN RA AND SPONDYLOARTHRITIDES. OBESITY REDUCES THE RATE OF REMISSION-RESPONSE. THE GISEA REGISTRY 64
Alternative Complement Pathway Activation in Nephrolithiasis 64
Imbalance of immune functions in progressive systemic sclerosis patients 64
Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: the experience of two Italian integrated Dermatology/Rheumatology outpatient clinics. 63
Totale 7.868
Salva come PNG Salva come JPEG
Categoria #
all - tutte 92.568
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 92.568
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.622 646 50 447 39 59 526 600 69 493 144 46 503
2020/20213.716 69 453 25 469 485 142 505 24 470 129 758 187
2021/20222.529 134 240 441 174 103 26 21 152 189 131 179 739
2022/20237.628 605 368 158 745 734 854 15 537 3.241 57 213 101
2023/20241.937 418 114 116 257 149 476 33 103 10 81 52 128
2024/202563 63 0 0 0 0 0 0 0 0 0 0 0
Totale 24.681